EA027511B1 - Способ отделения популяции парвовирусных вирионов от популяции бакуловирусных вирионов - Google Patents
Способ отделения популяции парвовирусных вирионов от популяции бакуловирусных вирионов Download PDFInfo
- Publication number
- EA027511B1 EA027511B1 EA201490583A EA201490583A EA027511B1 EA 027511 B1 EA027511 B1 EA 027511B1 EA 201490583 A EA201490583 A EA 201490583A EA 201490583 A EA201490583 A EA 201490583A EA 027511 B1 EA027511 B1 EA 027511B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- filter
- virions
- sample
- baculovirus
- virus
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 87
- 210000002845 virion Anatomy 0.000 title claims abstract description 84
- 239000011148 porous material Substances 0.000 claims abstract description 31
- 241000701447 unidentified baculovirus Species 0.000 claims description 86
- 241000125945 Protoparvovirus Species 0.000 claims description 39
- 238000001914 filtration Methods 0.000 claims description 30
- 239000012528 membrane Substances 0.000 claims description 27
- 239000000706 filtrate Substances 0.000 claims description 14
- 229920002678 cellulose Polymers 0.000 claims description 12
- 239000001913 cellulose Substances 0.000 claims description 12
- QKSIFUGZHOUETI-UHFFFAOYSA-N copper;azane Chemical compound N.N.N.N.[Cu+2] QKSIFUGZHOUETI-UHFFFAOYSA-N 0.000 claims description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 9
- -1 polytetrafluoroethylene Polymers 0.000 claims description 9
- 241000702421 Dependoparvovirus Species 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 claims description 6
- 239000002033 PVDF binder Substances 0.000 claims description 5
- 238000001042 affinity chromatography Methods 0.000 claims description 5
- 230000009089 cytolysis Effects 0.000 claims description 5
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 5
- 239000003599 detergent Substances 0.000 claims description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 5
- 239000004695 Polyether sulfone Substances 0.000 claims description 4
- 229920002301 cellulose acetate Polymers 0.000 claims description 4
- 229920006393 polyether sulfone Polymers 0.000 claims description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 4
- 239000000020 Nitrocellulose Substances 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 3
- 239000004743 Polypropylene Substances 0.000 claims description 3
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000004255 ion exchange chromatography Methods 0.000 claims description 3
- 229920001220 nitrocellulos Polymers 0.000 claims description 3
- 229920002492 poly(sulfone) Polymers 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- 239000004627 regenerated cellulose Substances 0.000 claims description 3
- 230000000717 retained effect Effects 0.000 claims description 2
- 241000700605 Viruses Species 0.000 description 109
- 239000000523 sample Substances 0.000 description 57
- 239000002245 particle Substances 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 46
- 230000003612 virological effect Effects 0.000 description 27
- 208000015181 infectious disease Diseases 0.000 description 25
- 241000238631 Hexapoda Species 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 21
- 239000000047 product Substances 0.000 description 19
- 230000002458 infectious effect Effects 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 239000013598 vector Substances 0.000 description 14
- 238000000926 separation method Methods 0.000 description 13
- 239000012535 impurity Substances 0.000 description 11
- 238000001415 gene therapy Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000013603 viral vector Substances 0.000 description 9
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000004140 cleaning Methods 0.000 description 8
- 238000011100 viral filtration Methods 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 229940127557 pharmaceutical product Drugs 0.000 description 7
- 238000011045 prefiltration Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 239000013607 AAV vector Substances 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000012466 permeate Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 241000255777 Lepidoptera Species 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 229920001940 conductive polymer Polymers 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 238000009616 inductively coupled plasma Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000007918 pathogenicity Effects 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 241001068295 Replication defective viruses Species 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011210 chromatographic step Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000012510 hollow fiber Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000001728 nano-filtration Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 1
- 241000537222 Betabaculovirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100264195 Caenorhabditis elegans app-1 gene Proteins 0.000 description 1
- 101500012753 Camponotus floridanus Pyrokinin 4 Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101100505236 Human herpesvirus 6B (strain Z29) gM gene Proteins 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 241000219823 Medicago Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/16—Feed pretreatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/08—Polysaccharides
- B01D71/10—Cellulose; Modified cellulose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/26—Further operations combined with membrane separation processes
- B01D2311/2623—Ion-Exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/26—Further operations combined with membrane separation processes
- B01D2311/2649—Filtration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14351—Methods of production or purification of viral material
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Water Supply & Treatment (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532176P | 2011-09-08 | 2011-09-08 | |
| EP11180594 | 2011-09-08 | ||
| PCT/NL2012/050619 WO2013036118A1 (en) | 2011-09-08 | 2012-09-07 | Removal of contaminating viruses from aav preparations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201490583A1 EA201490583A1 (ru) | 2014-07-30 |
| EA027511B1 true EA027511B1 (ru) | 2017-08-31 |
Family
ID=47832422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201490583A EA027511B1 (ru) | 2011-09-08 | 2012-09-07 | Способ отделения популяции парвовирусных вирионов от популяции бакуловирусных вирионов |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9840694B2 (https=) |
| EP (3) | EP3425044A1 (https=) |
| JP (2) | JP6198278B2 (https=) |
| KR (1) | KR101961347B1 (https=) |
| CN (2) | CN107502597A (https=) |
| AU (1) | AU2012304993B2 (https=) |
| BR (1) | BR112014005255A2 (https=) |
| CA (1) | CA2847604A1 (https=) |
| DK (1) | DK2744895T3 (https=) |
| EA (1) | EA027511B1 (https=) |
| ES (1) | ES2558168T3 (https=) |
| HU (1) | HUE026579T2 (https=) |
| IL (1) | IL231398A (https=) |
| MX (1) | MX349601B (https=) |
| PL (1) | PL2744895T3 (https=) |
| PT (1) | PT2744895E (https=) |
| SI (1) | SI2744895T1 (https=) |
| WO (1) | WO2013036118A1 (https=) |
| ZA (1) | ZA201401714B (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2744895E (pt) * | 2011-09-08 | 2016-02-08 | Uniqure Ip Bv | Remoção de vírus contaminantes de preparações de aav |
| CN120174012A (zh) | 2013-10-24 | 2025-06-20 | 优尼科Ip有限公司 | 用于基因治疗神经疾病的aav-5假型载体 |
| WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| CA3193811A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| CN119876138A (zh) | 2014-11-14 | 2025-04-25 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| FI3224376T4 (fi) * | 2014-11-28 | 2023-08-31 | Dna-epäpuhtaudet koostumuksessa, joka käsittää parvovirusvirionin | |
| HK1245326A1 (zh) | 2014-12-12 | 2018-08-24 | Voyager Therapeutics, Inc. | 用於生产scaav的组合物和方法 |
| AU2015370903B2 (en) | 2014-12-24 | 2021-06-17 | Uniqure Ip B.V. | RNAi induced huntingtin gene suppression |
| EP3054007A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CA3024448C (en) | 2016-05-18 | 2025-09-09 | Voyager Therapeutics, Inc. | MODULATING POLYNUCLEOTIDES |
| CA3024449A1 (en) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
| WO2018044933A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハンチントン病治療組成物および方法 |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
| US20200263199A1 (en) | 2017-09-29 | 2020-08-20 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| SG11202006056RA (en) | 2018-01-17 | 2020-07-29 | Meiragtx Uk Ii Ltd | A modified raav capsid protein for gene therapy |
| SG11202011296VA (en) | 2018-05-15 | 2020-12-30 | Voyager Therapeutics Inc | Compositions and methods for the treatment of parkinson's disease |
| EP3850098A1 (en) | 2018-09-12 | 2021-07-21 | uniQure IP B.V. | Rnai induced c9orf72 suppression for the treatment of als/ftd |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| JP2022514112A (ja) * | 2018-10-15 | 2022-02-09 | リジェネクスバイオ インコーポレイテッド | 複製欠損型ウイルスベクター及びウイルスの感染性を測定するための方法 |
| WO2020104480A1 (en) | 2018-11-19 | 2020-05-28 | Uniqure Biopharma B.V. | Adeno-associated virus vectors for expressing fviii mimetics and uses thereof |
| CA3119721A1 (en) | 2018-11-19 | 2020-05-28 | Uniqure Ip B.V. | A companion diagnostic to monitor the effects of gene therapy |
| WO2020104469A1 (en) | 2018-11-19 | 2020-05-28 | Uniqure Ip B.V. | Method and means to deliver mirna to target cells |
| WO2020104295A1 (en) | 2018-11-19 | 2020-05-28 | Uniqure Ip B.V. | Rnai induced reduction of ataxin-3 for the treatment of spinocerebellar ataxia type 3 |
| JP2022522995A (ja) * | 2019-01-18 | 2022-04-21 | ボイジャー セラピューティクス インコーポレイテッド | Ａａｖ粒子を生成するための方法及びシステム |
| US11718834B2 (en) | 2019-02-15 | 2023-08-08 | Sangamo Therapeutics, Inc. | Compositions and methods for producing recombinant AAV |
| WO2020219897A1 (en) * | 2019-04-24 | 2020-10-29 | Biogen Ma Inc. | Methods for production of recombinant adeno-associated viruses |
| PL3999119T3 (pl) | 2019-07-15 | 2025-02-10 | Meiragtx Uk Ii Limited | Modyfikowane białka kapsydu aav do leczenia choroby zapalnej stawów |
| WO2021053018A1 (en) | 2019-09-16 | 2021-03-25 | Uniqure Ip B.V. | Targeting misspliced transcripts in genetic disorders |
| IL293397A (en) | 2019-12-04 | 2022-07-01 | Sangamo Therapeutics Inc | New preparations and methods for the production of recombinant aav |
| JP7737374B2 (ja) * | 2019-12-12 | 2025-09-10 | イー・エム・デイー・ミリポア・コーポレイシヨン | 透析濾過緩衝液を用いて増強したウイルス濾過 |
| WO2021154923A2 (en) * | 2020-01-29 | 2021-08-05 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
| JP7390466B2 (ja) * | 2020-02-28 | 2023-12-01 | 旭化成メディカル株式会社 | ウイルスクリアランス性能の評価方法 |
| CA3174872A1 (en) | 2020-04-07 | 2021-10-14 | Sander Jan Hendrik Van Deventer | Gene constructs for silencing angiopoietin-like 3 (angptl3) and uses thereof |
| CN115427561B (zh) | 2021-03-09 | 2024-06-04 | 辉大(上海)生物科技有限公司 | 工程化CRISPR/Cas13系统及其用途 |
| US20240157306A1 (en) * | 2021-03-30 | 2024-05-16 | 3M Innovative Properties Company | Hollow-fiber membrane and method making thereof |
| CN117120152A (zh) * | 2021-03-30 | 2023-11-24 | 3M创新有限公司 | 包含聚砜和聚噁唑啉的中空纤维膜及其制造方法 |
| WO2022214635A1 (en) | 2021-04-08 | 2022-10-13 | Stichting Vu | Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders |
| CA3219847A1 (en) | 2021-06-02 | 2022-12-08 | Sander Jan Hendrik Van Deventer | Adeno-associated virus vectors modified to bind high-density lipoprotein |
| EP4359525A1 (en) | 2021-06-21 | 2024-05-01 | uniQure biopharma B.V. | Gene constructs for silencing alpha-synuclein and uses thereof |
| CN117836010A (zh) | 2021-06-21 | 2024-04-05 | 优尼科生物制药有限公司 | 改进的裂解程序 |
| WO2023283962A1 (en) | 2021-07-16 | 2023-01-19 | Huigene Therapeutics Co., Ltd. | Modified aav capsid for gene therapy and methods thereof |
| EP4508213A1 (en) | 2022-04-12 | 2025-02-19 | uniQure biopharma B.V. | Nucleic acid regulation of apoe |
| EP4508215A1 (en) | 2022-04-12 | 2025-02-19 | uniQure biopharma B.V. | Novel systems for nucleic acid regulation |
| WO2023198663A1 (en) | 2022-04-12 | 2023-10-19 | Uniqure Biopharma B.V. | Nucleic acid regulation of snca |
| WO2023198702A1 (en) | 2022-04-12 | 2023-10-19 | Uniqure Biopharma B.V. | Nucleic acid regulation of c9orf72 |
| US20240209324A1 (en) * | 2022-12-22 | 2024-06-27 | Cytiva Us Llc | Virus separation |
| EP4698555A1 (en) | 2023-04-18 | 2026-02-25 | uniQure biopharma B.V. | Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs |
| WO2024218204A1 (en) | 2023-04-18 | 2024-10-24 | Uniqure Biopharma B.V. | Gene delivery vehicles comprising rna and antibodies |
| AU2024313758A1 (en) | 2023-06-23 | 2026-01-08 | Uniqure Biopharma B.V. | Novel fragile x constructs |
| AU2024337260A1 (en) | 2023-09-04 | 2026-03-12 | Uniqure Biopharma B.V. | Novel neurotropic recombinant adeno-associated virus particles |
| AU2024357870A1 (en) | 2023-10-11 | 2026-04-23 | Uniqure Biopharma B.V. | Further novel systems for nucleic acid regulation |
| AU2024360616A1 (en) | 2023-10-11 | 2026-04-23 | Uniqure Biopharma B.V. | Novel nucleic acid regulation of huntingtin gene |
| WO2025078602A1 (en) | 2023-10-11 | 2025-04-17 | Uniqure Biopharma B.V. | Nucleic acid regulation of msh3 in repeat expansion disorders |
| WO2025114524A1 (en) | 2023-11-30 | 2025-06-05 | Uniqure Biopharma B.V. | Formulations for viral drug products |
| WO2025219443A1 (en) | 2024-04-19 | 2025-10-23 | Uniqure Biopharma B.V. | Nucleic acid for a1at regulation |
| WO2026041788A1 (en) | 2024-08-22 | 2026-02-26 | Uniqure Biopharma B.V | Novel bbb interacting capsids |
| WO2026041782A1 (en) | 2024-08-22 | 2026-02-26 | Uniqure Biopharma B.V. | Novel raav capsids |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6479273B1 (en) * | 1997-03-06 | 2002-11-12 | Medigene Aktiengesellschaft | Filtration method for separating viruses |
| WO2010148143A1 (en) * | 2009-06-16 | 2010-12-23 | Genzyme Corporation | Improved methods for purification of recombinant aav vectors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| WO1996011272A2 (de) | 1994-10-07 | 1996-04-18 | Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung |
| US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
| ES2340230T3 (es) | 1998-11-10 | 2010-05-31 | University Of North Carolina At Chapel Hill | Vectores viricos y sus procedimientos de preparacion y administracion. |
| US6593123B1 (en) * | 2000-08-07 | 2003-07-15 | Avigen, Inc. | Large-scale recombinant adeno-associated virus (rAAV) production and purification |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| WO2003074714A1 (en) | 2002-03-05 | 2003-09-12 | Stichting Voor De Technische Wetenschappen | Baculovirus expression system |
| US20050009168A1 (en) * | 2003-05-12 | 2005-01-13 | Robbins Joan Marie | Methods and apparatus for Adeno associated virus purification |
| KR101589259B1 (ko) * | 2006-06-21 | 2016-02-01 | 유니큐어 아이피 비.브이. | 곤충세포 내 ａａｖ의 생산에 유용한 ａａｖ-ｒｅｐ78의 번역을 위한 변형된 개시 코돈을 갖는 벡터 |
| WO2008109721A1 (en) * | 2007-03-06 | 2008-09-12 | Introgen Therapeutics, Inc. | Chromatographic methods for assessing adenovirus purity |
| US20100323429A1 (en) * | 2008-04-10 | 2010-12-23 | Yu-Chen Hu | Methods for purifying baculovirus |
| DK2529020T3 (en) * | 2010-01-28 | 2018-08-06 | Childrens Hospital Philadelphia | SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY |
| PT2744895E (pt) | 2011-09-08 | 2016-02-08 | Uniqure Ip Bv | Remoção de vírus contaminantes de preparações de aav |
-
2012
- 2012-09-07 PT PT127586634T patent/PT2744895E/pt unknown
- 2012-09-07 WO PCT/NL2012/050619 patent/WO2013036118A1/en not_active Ceased
- 2012-09-07 EP EP18191023.3A patent/EP3425044A1/en not_active Withdrawn
- 2012-09-07 SI SI201230372T patent/SI2744895T1/sl unknown
- 2012-09-07 CN CN201710697343.1A patent/CN107502597A/zh active Pending
- 2012-09-07 KR KR1020147009146A patent/KR101961347B1/ko not_active Expired - Fee Related
- 2012-09-07 MX MX2014002733A patent/MX349601B/es active IP Right Grant
- 2012-09-07 EP EP12758663.4A patent/EP2744895B1/en active Active
- 2012-09-07 AU AU2012304993A patent/AU2012304993B2/en not_active Ceased
- 2012-09-07 EP EP15186937.7A patent/EP2990477B8/en not_active Revoked
- 2012-09-07 ES ES12758663.4T patent/ES2558168T3/es active Active
- 2012-09-07 BR BR112014005255A patent/BR112014005255A2/pt active Search and Examination
- 2012-09-07 JP JP2014529633A patent/JP6198278B2/ja not_active Expired - Fee Related
- 2012-09-07 US US14/343,884 patent/US9840694B2/en not_active Expired - Fee Related
- 2012-09-07 EA EA201490583A patent/EA027511B1/ru not_active IP Right Cessation
- 2012-09-07 CN CN201280049899.5A patent/CN103857790B/zh not_active Expired - Fee Related
- 2012-09-07 HU HUE12758663A patent/HUE026579T2/en unknown
- 2012-09-07 PL PL12758663T patent/PL2744895T3/pl unknown
- 2012-09-07 DK DK12758663.4T patent/DK2744895T3/en active
- 2012-09-07 CA CA2847604A patent/CA2847604A1/en not_active Abandoned
-
2014
- 2014-03-06 IL IL231398A patent/IL231398A/en active IP Right Grant
- 2014-03-07 ZA ZA2014/01714A patent/ZA201401714B/en unknown
-
2017
- 2017-06-27 JP JP2017125458A patent/JP6624690B2/ja not_active Expired - Fee Related
- 2017-12-08 US US15/836,220 patent/US10253301B2/en not_active Expired - Fee Related
-
2019
- 2019-03-20 US US16/359,593 patent/US20190218523A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6479273B1 (en) * | 1997-03-06 | 2002-11-12 | Medigene Aktiengesellschaft | Filtration method for separating viruses |
| WO2010148143A1 (en) * | 2009-06-16 | 2010-12-23 | Genzyme Corporation | Improved methods for purification of recombinant aav vectors |
Non-Patent Citations (4)
| Title |
|---|
| GERD KERN: "Virus removal by filtration", BIOPHARM INTERNATIONAL, vol. 19, no. 10, 1 January 2006 (2006-01-01), pages 32 - 41, XP055017438 * |
| J. BLüMEL ; A. STüHLER: "Wichtige Aspekte der Virussicherheit bei Neuartigen Therapien", BUNDESGESUNDHEITSBLATT - GESUNDHEITSFORSCHUNG - GESUNDHEITSSCHUTZ, SPRINGER, BERLIN, DE, vol. 53, no. 1, 26 November 2009 (2009-11-26), Berlin, DE, pages 38 - 44, XP019765204, ISSN: 1437-1588 * |
| JOHANNES BLÜMEL: "Virus Safety Aspects of advanced Therapies", 25 November 2008 (2008-11-25), pages 1 - 18, XP055016970, Retrieved from the Internet <URL:http://www.dgra.de/fortbildung/pdf/workshops/20081125_pei/4-5-bluemel.pdf> [retrieved on 20120119] * |
| RUEDA, P. ; FOMINAYA, J. ; LANGEVELD, J.P. ; BRUSCHKE, C. ; VELA, C. ; CASAL, J.: "Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 19, no. 7-8, 22 November 2000 (2000-11-22), AMSTERDAM, NL, pages 726 - 734, XP027322027, ISSN: 0264-410X * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA027511B1 (ru) | Способ отделения популяции парвовирусных вирионов от популяции бакуловирусных вирионов | |
| Liu et al. | Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins | |
| KR102930150B1 (ko) | 재조합 aav 생성을 위한 음이온 교환 크로마토그래피 | |
| ES2472429T3 (es) | Método para la purificación de partículas de adenovirus a partir de cultivos de alta densidad celular | |
| US20240141377A1 (en) | Controlled expression of viral proteins | |
| US20030036088A1 (en) | Filtration process for separating viruses | |
| KR20230011935A (ko) | 아데노 연관 바이러스 입자 또는 아데노바이러스를 정제하기 위한 방법 및 조성물 | |
| Tijssen et al. | Parvoviridae. Structure and reproduction of densonucleosis viruses | |
| US20240287545A1 (en) | Improved lysis procedures | |
| Michalsky et al. | Concentration of the baculovirus Autographa californica M nucleopolyhedrovirus (AcMNPV) by ultrafiltration | |
| HK1220229B (en) | Removal of contaminating viruses from aav preparations | |
| HK1262994A1 (en) | Removal of contaminating viruses from aav preparations | |
| US20260085328A1 (en) | Controlled expression of viral proteins | |
| Gurda et al. | Production and purification of viruses for structural studies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |